Trial Profile
A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2019
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms CONNECTED
- Sponsors Biogen
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.
- 11 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 02 May 2016 Status changed from not yet recruiting to recruiting.